Ulcer Drug Patents Spark Court Battle
The suit comes in response to an Abbreviated New Drug Application filed by Ranbaxy with the U.S. Food and Drug Administration, according to Astrazeneca. The suit was filed in the U.S. District Court for the District of New Jersey.
The suit claims infringement based on Ranbaxy’s stated intent to market a generic...
To view the full article, register now.